Publications by authors named "John Polzer"

Claim this Profile
T
The ALSFRS-R Summit: a global call to action on the use of the ALSFRS-R in ALS clinical trials.
Angela Genge, Jesse M Cedarbaum, Jeremy Shefner, Adriano Chio, Ammar Al-Chalabi, John Polzer

Amyotroph Lateral Scler Frontotemporal Degener· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic and predictive value of circulating tumor cells and CXCR4 expression as biomarkers for a CXCR4 peptide antagonist in combination with carboplatin-etoposide in small cell lung cancer: exploratory analysis of a phase II study.
Ravi Salgia, R Waide Weaver, Michael McCleod, John R Stille, S Betty Yan, John Polzer

Invest New Drugs· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized phase II study of LY2510924 and carboplatin/etoposide versus carboplatin/etoposide in extensive-disease small cell lung cancer.
Ravi Salgia, John R Stille, R Waide Weaver, Michael McCleod, Oday Hamid, John Polzer

Lung Cancer· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Randomized, Open-Label Phase 2 Study of the CXCR4 Inhibitor LY2510924 in Combination with Sunitinib Versus Sunitinib Alone in Patients with Metastatic Renal Cell Carcinoma (RCC).
John D Hainsworth, James A Reeves, Joseph R Mace, Edward J Crane, Oday Hamid, John Polzer

Target Oncol· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Detecting Data Quality Issues in Clinical Trials: Current Practices and Recommendations.
David Knepper, Christian Fenske, Patrick Nadolny, Alun Bedding, Elena Gribkova, John Polzer

Ther Innov Regul Sci· January 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I trial of LY2510924, a CXCR4 peptide antagonist, in patients with advanced cancer.
Matthew D Galsky, Nicholas J Vogelzang, Paul Conkling, Eyas Raddad, John Polzer

Clin Cancer Res· July 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Double-blind, randomized study evaluating the glycemic and anti-inflammatory effects of subcutaneous LY2189102, a neutralizing IL-1β antibody, in patients with type 2 diabetes.
Joanne Sloan-Lancaster, Eyas Abu-Raddad, John Polzer, Jeffrey W Miller, Joel C Scherer

Diabetes Care· August 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Meta-analysis of aggression or hostility events in randomized, controlled clinical trials of atomoxetine for ADHD.
John Polzer, Mark E Bangs, Shuyu Zhang, Mary Anne Dellva, Sitra Tauscher-Wisniewski

Biol Psychiatry· March 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A review of treatment-emergent adverse events during olanzapine clinical trials in elderly patients with dementia.
Ludmila A Kryzhanovskaya, Dilip V Jeste, Carrie A Young, John P Polzer, Tamra E Roddy

J Clin Psychiatry· June 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis